| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Apr 10, 2017CSL Behring marks World Hemophilia Day by donating its bleeding disorders medicines to the World Federation of Hemophilia (WFH).
10 Apr 2017 MONTREAL and KING OF PRUSSIA, Pa. — 10 April 2017 CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia...
-
Mar 31, 2017CSL Behring Sponsors the First Network of its Kind on the African Continent
31 Mar 2017 LIVINGSTONE, ZAMBIA — 31 March 2017 Global biotherapeutics leader CSL Behring today announced its commitment to sponsor the Jeffrey Modell North African Network, which will establish...
-
Mar 29, 2017CSL Behring’s Local Empowerment for Advocacy Development Grant helps rare disease patient groups and patients protect access to lifesaving therapies.
29 Mar 2017 KING OF PRUSSIA, Pa — 29 March 2017 Patients are the most compelling advocates for access to care, which is why CSL Behring awards Local Empowerment for Advocacy Development (LEAD)...
-
Mar 22, 2017The New England Journal of Medicine published data from the COMPACT study which demonstrated the safety and efficacy of CSL830 to prevent HAE attacks.
22 Mar 2017 KING OF PRUSSIA, Pa — 22 March 2017 Median reduction in hereditary angioedema (HAE) attack rate relative to placebo was 95% at the highest dose studied Data show up to 40% of HAE...
-
Mar 1, 2017PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy
01 Mar 2017 KING OF PRUSSIA, Pa — 01 March 2017 Global biotherapeutics leader CSL Behring announced today that it has completed the largest ever Chronic Inflammatory Demyelinating Polyneuropathy...
-
Feb 14, 2017FDA Accepts CSL Behring’s Biologics License Application Supplement for Using Privigen® to Treat Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), a Rare Neurological Condition
14 Feb 2017 KING OF PRUSSIA, Pa — 14 February 2017 Global biotherapeutics leader CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the...
-
Jan 9, 2017- CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A
09 Jan 2017 MARBURG, Germany — 09 January 2017 CSL Behring’s AFSTYLA is the first and only single-chain therapy for haemophilia A The therapy has been specifically designed for greater...
-
Jan 5, 2017
05 Jan 2017 CAMBRIDGE, MA — 05 January 2017 Momenta to receive $50 million upfront license fee and up to 4550 million in potential milestone payments from CSL Momenta to host a conference call...
-
Dec 21, 2016CSL released its 2015-2016 Corporate Responsibility Report, which details company performance in key social, environmental and economic priority areas.
21 Dec 2016 CSL Limited (ASX:CSL), parent company of CSL Behring, has recorded another strong performance in corporate responsibility, outlining in its 2015/16 report the top 15 sustainability...
-
Dec 21, 2016
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec et risus odio. Vivamus pellentesque, tortor a tempor semper, massa nulla placerat augue, sit amet convallis tellus orci ut massa....
-
Dec 21, 2016
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec et risus odio. Vivamus pellentesque, tortor a tempor semper, massa nulla placerat augue, sit amet convallis tellus orci ut massa....
-
Dec 21, 2016
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec et risus odio. Vivamus pellentesque, tortor a tempor semper, massa nulla placerat augue, sit amet convallis tellus orci ut massa....
-
Dec 14, 2016Health Canada has approved AFSTYLA, CSL Behring’s novel long-lasting recombinant factor VIII single-chain therapy for adults and children with hemophilia A.
14 Dec 2016 AFSTYLA is the first and only single-chain recombinant factor VIII for hemophilia A, specifically designed for long-lasting protection from bleeds with twice-weekly dosing available In...
-
Dec 3, 2016Global biotherapeutics leader CSL Behring today announced new results from its Phase III clinical development program evaluating IDELVION® [Coagulation Factor IX (Recombinant), Albumin Fusion Protein], the company’s novel, long-acting recombinant albumin fusion protein for the treatment of hemophilia B.
03 Dec 2016 Analysis of clinical trial efficacy results and estimated factor IX levels suggests that patients who maintain factor IX activity levels above 5 and 10 percent have significantly...
-
Dec 2, 2016CSL Behring’s RAPID Extension Study data confirms disease-modifying effect of Respreeza® in patients with AATD.
02 Dec 2016 Global biotherapeutics leader CSL Behring announced today that data from the RAPID Open Label Extension study, conducted in patients with alpha-1 antitrypsin deficiency (AATD),...
-
Nov 15, 2016AEGIS-1 Phase 2b study meets co-primary endpoints of hepatic and renal safety and demonstrates proof of mechanism - results were presented at AHA 2016.
15 Nov 2016 CSL Behring today announced positive results from AEGIS-I, a Phase 2b safety and proof of mechanism clinical study of CSL112, a novel apolipoprotein A-I (apoA-I) infusion therapy....
-
Nov 14, 2016Global biotherapeutics leader CSL Behring announced today that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended granting marketing authorisation for AFSTYLA® [Recombinant Human Coagulation Factor VIII, Single Chain] for patients with haemophilia A.
14 Nov 2016 CHMP positive opinion moves AFSTYLA one step closer to approval in the European Union AFSTYLA is the first and only single-chain therapy for haemophilia A. The therapy has been...
-
Oct 27, 2016One of the world’s top specialty biotherapeutics companies, CSL Behring continues to introduce innovations to address unmet medical needs or enhance current treatments
27 Oct 2016 Marcum LLP and Philadelphia SmartCEO magazine have recognized CSL Behring with the 2016 Innovator Breakthrough Award for developing novel products that save lives and improve quality...
-
Oct 7, 2016Many Rare Disease Patients Would Not Have Treatments Available to Them without an Adequate Supply of Human Plasma, and patients call plasma donors "heroes" for their lifesaving contributions.
07 Oct 2016 More than 1,000 plasma donations may be needed to treat one adult patient with a rare disease for a year During International Plasma Awareness Week, plasma donors are recognized by...
-
Oct 3, 2016CSL Behring announced that the Australian Therapeutic Goods Administration (TGA) has approved IDELVION®[albutrepenonacog alfa] in patients with haemophilia B (congenital factor IX deficiency).
03 Oct 2016 IDELVION is a long-acting recombinant albumin fusion protein for children and adults with haemophilia B, and is the first CSL Behring recombinant factor product to receive TGA approval...
-
Sep 29, 2016Global biotherapeutics leader CSL Behring announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved IDELVION® [Albutrepenonacog Alfa], its innovative, long-acting albumin fusion protein linking recombinant coagulation factor IX with recombinant albumin for the prevention of bleeding tendency in patients with factor IX deficiency.
29 Sep 2016 IDELVION® delivers high-level protection from bleeds by maintaining factor IX activity levels at an average of 20 percent in patients treated prophylactically every 7-days and an...
-
Sep 21, 2016CSL Behring is proud to be a platinum sponsor of the 17th Biennial Meeting of the European Society for Immunodeficiencies (ESID) this week in Barcelona
21 Sep 2016 Hizentra® - the only 20% concentration SCIG with a proven track record of safety and efficacy for over 6 years; trusted by more than 18,000 patients and providers worldwide Privigen®...
-
Sep 16, 2016General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in recognition of his professional accomplishments and passion for ethical leadership
16 Sep 2016 General Counsel Greg Boss of global biotherapeutics leader CSL Limited today accepted the World Recognition of Distinguished General Counsel from the Directors Roundtable in...
-
Sep 6, 2016CSL Behring is hosting an Expert Forum "Modifying Alpha-1 Antitrypsin Deficiency Related Emphysema" today during the 26th International Congress of the European Respiratory Society (ERS) in London.
06 Sep 2016 Global biotherapeutics leader CSL Behring will host an Expert Forum about Alpha-1 Antitrypsin Deficiency (AATD) today during the 26th International Congress of the European Respiratory...
-
Aug 30, 2016The U.S. Food and Drug Administration (FDA) has accepted CSL Behring’s application for its low volume subcutaneous (SC) C1-Esterase Inhibitor (C1-INH) Human replacement therapy for treating HAE. Upon FDA approval, CSL830 will be the first and only low volume, subcutaneous, prophylactic treatment option for HAE patients.
30 Aug 2016 CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for its low-volume subcutaneous...